Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Raises Price Target to $93
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse maintains a Strong Buy rating on Apellis Pharmaceuticals and raises the price target from $92 to $93.
November 02, 2023 | 8:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James maintains a Strong Buy rating on Apellis Pharmaceuticals and raises the price target, which could positively impact the stock.
The Strong Buy rating maintained by Raymond James, coupled with a raised price target, indicates a positive outlook for Apellis Pharmaceuticals. This could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100